A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: beyond (184), exceeding (120)

Finance and Performance Reports 2024-25 Month 5 August 2024

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2024-25 Month 5 N
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2024-25-Month-5-August-2024.pdf

Avelumab-Axitinib

Description
Chemotherapy Protocol RENAL CELL AVELUMAB-AXITINIB Regimen • Renal Cell - Avelumab-Axitinib Indication • Unresectabl
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Axitinib-Avelumab.pdf

RPACEBOM - Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine

Description
Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-METHOTREXATEPREDNISOLONE-RITUXIMAB-VINCRISTINE Regimen (RPACEBOM) Lymp
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RPACEBOM-Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine.pdf

Carfilzomib-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib-Dexamethasone (20) Regimen • Myeloma – Carfilzomib-Dexamethasone (20)
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib-dexamethasone20-ver1.pdf

Carfilzomib(14 day)-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib (14 day)-Dexamethasone (20) Regi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib14-day-dexamethasone20-ver1.pdf

UHS register of interests June 2025

Description
Employee Name Aarvold, Dr Alice Beatrice Rachel Aarvold, Dr Alice Beatrice Rachel Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhug
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/UHS-register-of-interests-June-2025.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description
Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexameth
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Finance and Performance Reports 2023-24 Month 10 - January 2024

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2023-24 Month 10 10.3 Ian Howard – Chi
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-10-January-2024.pdf

CEOP-Cyclophosphamide-Etoposide-Prednisolone-Vincristine Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE-PREDNISOLONE-VINCRISTINE Regimen (CEOP) Lymphoma –
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/CEOP-Cyclophosphamide-Etoposide-Prednisolone-Vincristine-Ver-1.2.pdf

ObinutuzumabVenetoclax LowRisk

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indication • Chron
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf
41 to 50 of 869
Previous … 3 4 5 6 7 … Next